ArticleCancer immunology, immunotherapy : CII2011

An engineered superantigen SEC2 exhibits promising antitumor activity and low toxicity.

Mingkai Xu et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.